• cholangiocarcinoma
• breast cancer (BC) 2

 

• AKT inhibitor
• capivasertib based treatment
• capivasertib plus paclitaxel
• ipatasertib based treatment
• ipatasertib plus paclitaxel
• antibody–drug conjugate
• sacituzumab govitecan
• trastuzumab deruxtecan
• trastuzumab emtansine
• trastuzumab emtasine plus endocrine therapy
• aurora kinase inhibitors
• alisertib plus paclitaxel
• biguanide
• metformin
• celecoxib plus endocrine therapy
• cyclin inhibitor
• abemaciclib based treatment
• abemaciclib plus aromatase inhibitor
• abemaciclib plus endocrine therapy
• abemaciclib plus fulvestrant
• dalpiciclib plus fulvestrant
• palbociclib based treatment
• palbociclib
• palbociclib plus endocrine therapy
• palbociclib plus fulvestrant
• palbociclib plus letrozole
• ribociclib based treatment
• ribociclib plus endocrine therapy
• ribociclib plus fulvestrant
• ribociclib plus letrozole
• HDAC inhibitor
• entinostat plus exemestane
• tucidinostat based treatment
• tucidinostat plus exemestane
• HER inhibitor
• EGFR inhibitor
• afatinib based treatment
• afatinib plus vinorelbine
• HER2 inhibitor
• neratinib based treatment
• neratinib
• neratinib plus capecitabine
• pertuzumab based treatment
• pertuzumab plus trastuzumab
• pertuzumab plus trastuzumab plus docetaxel
• trastuzumab based treatment
• docetaxel plus carboplatin with trastuzumab followed by trastuzumab
• doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab
• trastuzumab plus endocrine therapy
• trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel
• tucatinib based treatment
• tucatinib plus trastuzumab plus capecitabine
• TKI anti HER1/EGFR and HER2/neu
• lapatinib based treatment
• lapatinib
• lapatinib plus capecitabine
• lapatinib plus fulvestrant
• lapatinib plus letrozole
• lapatinib plus trastuzumab
• IGF-1R inhibitors
• dalotuzumab plus ridaforolimus plus exemestane
• ganitumab plus endocrine therapy
• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus carboplatin plus nab-paclitaxel
• atezolizumab plus nab-paclitaxel
• atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide
• atezolizumab plus paclitaxel
• durvalumab based treatment
• durvalumab alone
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide
• pembrolizumab plus SoC
• Immunostimulant
• vaccine
• AE37 vaccine plus GM-CSF
• GP2 vaccine plus GM-CSF
• OBI-822/OBI-821 plus cyclophosphamide
• inetetamab plus vinorelbine
• mTOR inhibitors
• everolimus
• sapanisertib plus fulvestrant
• phosphoinositide 3-kinase (PI3K) inhibitor
• alpelisib based treatment
• alpelisib plus fulvestrant
• alpelisib plus letrozole
• buparlisib based treatment
• buparlisib plus fulvestrant
• buparlisib plus letrozole
• taselisib based treatment
• taselisib plus letrozole
• poly ADP-ribose polymerase (PARP) inhibitor
• olaparib
• talazoparib
• veliparib plus paclitaxel plus carboplatin
• target therapy
• margetuximab based treatment
• margetuximab plus chemotherapy
• VEGF(R) inhibitor
• bevacizumab based treatment
• bevacizumab plus trastuzumab plus docetaxel
• cediranib plus fulvestrant

• versus all
• vs antibody–drug conjugate
• vs trastuzumab emtansine
• vs chemotherapy
• vs doxorubicin plus cyclophosphamide followed by docetaxel
• vs non platinum-based chemotherapy
• vs nucleoside analogues (pyrimidine/purine)
• vs capecitabine
• vs taxanes
• vs paclitaxel
• vs paclitaxel followed by doxorubicin plus cyclophosphamide
• vs vinca alkaloids
• vs vinorelbine
• vs platinum-based chemotherapy
• vs platinum derivate
• vs platinum association
• vs paclitaxel plus carboplatin
• vs carboplatin plus nab-paclitaxel
• vs Standard of Care (SoC)
• vs placebo plus SoC
• vs endocrine therapy
• vs aromatase inhibitor
• vs exemestane
• vs exemestane plus ridaforolimus
• vs fulvestrant
• vs letrozole
• vs GM-CSF
• vs HER inhibitor
• vs HER2 inhibitor
• vs pertuzumab based treatment
• vs pertuzumab plus trastuzumab plus cyclophosphamide
• vs pertuzumab plus trastuzumab plus docetaxel
• vs trastuzumab based treatment
• vs docetaxel plus carboplatin with trastuzumab followed by trastuzumab
• vs trastuzumab
• vs trastuzumab plus capecitabine
• vs trastuzumab plus chemotherapy
• vs trastuzumab plus docetaxel
• vs trastuzumab plus endocrine therapy
• vs trastuzumab plus vinorelbine
• vs TKI anti HER1/EGFR and HER2/neu
• vs lapatinib based treatment
• vs lapatinib
• vs lapatinib plus capecitabine
• vs lapatinib plus epirubicin and cyclophosphamide followed by docetaxel
• vs non active control
• vs placebo

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Pathology:  la/mBC - HER2 positive - 2nd Line (L2);